Mangoceuticals reprices CEO's 2.1M stock options down 80% to $0.45 amid stock decline

Filed March 17, 2026 · Period ending March 16, 2026 · ~1 min read

Key Changes

• high

  CEO Jacob Cohen's stock options covering 2.13 million shares repriced to $0.45 from original prices of $2.30-$16.50, an 80% reduction on the largest grant issued just six months ago in September 2025.

  Item 5.02: Officer Compensation verify on EDGAR →
• high

  Repricing approved by Board after Compensation Committee recommendation, with Cohen recused from vote. New exercise price matches March 16 closing stock price of $0.45.

  Item 5.02: Officer Compensation verify on EDGAR →
• medium

  Company filed lawsuit against former consultant but provided no details on claims, dispute nature, or potential financial exposure in the 8-K disclosure.

  Item 7.01: Regulation FD verify on EDGAR →